Medication costs during an 18 month clinical trial of obesity treatment among patients encountered in primary care

Adam G Tsai, Elizabeth Juarez-Colunga, Sue Felton, Rebecca B Speer, Daniel H Bessesen, Adam J Atherly, Adam G Tsai, Elizabeth Juarez-Colunga, Sue Felton, Rebecca B Speer, Daniel H Bessesen, Adam J Atherly

Abstract

Background: Weight loss often leads to reductions in medication costs, particularly for weight-related conditions. We aimed to evaluate changes in medication costs from an 18 month study of weight loss among patients recruited from primary care.

Methods: Study participants (n = 79, average age = 56.3; 75.7 % female) with average BMI of 39.5 kg/m(2), plus one co-morbid condition of either diabetes/pre-diabetes, hypertension, abnormal cholesterol, or sleep apnea, were recruited from 2 internal medicine practices. All participants received intensive behavioral and dietary treatment during months 0-6, including subsidized access to portion-controlled foods for weight loss. From months 7-18, all participants were offered continued access to subsidized foods, and half of participants were randomly assigned to continue in-person visits ("Intensified Maintenance"), while the other half received materials by mail or e-mail ("Standard Maintenance"). Medication costs were evaluated at months 0, 6, and 18.

Results: Participants assigned to Intensified Maintenance maintained nearly all their lost weight, whereas those assigned to Standard Maintenance regained weight. However, no significant differences in medication costs were observed within or between groups during the 18 months of the trial. A reduction of nearly $30 per month (12.9 %) was observed among all participants from month 0 to month 6 (active weight loss phase), but this difference did not reach statistical significance.

Conclusions: A behavioral intervention that led to clinically significant weight loss did not lead to statistically significant reductions in medication costs. Substantial variability in medication costs and lack of a systematic approach by the study team to reduce medications may explain the lack of effect.

Trial registration: The trial was registered at (NCT01220089) on September 23, 2010.

Keywords: Clinical trial; Health care utilization; Medications; Obesity.

References

    1. Cawley J, Meyerhoefer C. The medical care costs of obesity: an instrumental variables approach. J Health Econ. 2012;31:219–230. doi: 10.1016/j.jhealeco.2011.10.003.
    1. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff. 2009;28:w822–w831. doi: 10.1377/hlthaff.28.5.w822.
    1. Narbro K, Agren G, Jonsson E, Naslund I, Sjostrom L, Peltonen M. Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. Arch Intern Med. 2002;162:2061–2069. doi: 10.1001/archinte.162.18.2061.
    1. Raebel MA, Newcomer SR, Reifler LM, et al. Chronic use of opioid medications before and after bariatric surgery. JAMA. 2013;310:1369–1376. doi: 10.1001/jama.2013.278344.
    1. Collins RW, Anderson JW. Medication cost savings associated with weight loss for obese non-insulin-dependent diabetic men and women. Prev Med. 1995;24:369–374. doi: 10.1006/pmed.1995.1060.
    1. Anderson JW, Jhaveri MA. Reductions in medications with substantial weight loss with behavioral intervention. Curr Clin Pharmacol. 2010;5:232–238. doi: 10.2174/157488410793352030.
    1. Redmon JB, Bertoni AG, Connelly S, et al. Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care. 2010;33:1153–1158. doi: 10.2337/dc09-2090.
    1. Tsai AG, Wadden TA, Volger S, et al. Cost-effectiveness of a primary care intervention to treat obesity. Int J Obes. 2013;37(S1):S31–S37. doi: 10.1038/ijo.2013.94.
    1. Trogdon J, Finkelstein EA, Reyes M, Dietz WH. A return-on-investment simulation model of workplace obesity interventions. J Occup Environ Med. 2009;51(7):751–758. doi: 10.1097/JOM.0b013e3181a86656.
    1. Wadden TA, Butryn ML, Hong PS, Tsai AG. Behavioral treatment of obesity in patients encountered in primary care settings. JAMA. 2014;312(17):1779–1791. doi: 10.1001/jama.2014.14173.
    1. Tsai AG, Felton S. Six month outcomes of a primary care-based weight loss trial using a lay-trained counselor. J Obes Weight Loss Ther. 2014;4:209.
    1. United States Department of Veterans Affairs. Drug Pharmaceutial Prices: Federal Supply Schedule. Available at: . Accessed November 11, 2012.
    1. Levinson DR, Office of the Inspector General. Medicaid Drug Price Comparison: Average Sales Price to Average Wholesale Price, 2005. OEI-03–05–00200. Available at: . Accessed April 2, 2014.
    1. Levinson DR, Office of the Inspector General. Medicaid Drug Price Comparisons: Average Manufacturer Price to Published Prices, 2005. OEI-05–05–00240. Available at: . Accessed April 2, 2014.
    1. Duan N. Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc. 1983;78:605–610. doi: 10.1080/01621459.1983.10478017.
    1. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998;17:283–295. doi: 10.1016/S0167-6296(98)00025-3.
    1. Griswold M, Parmigiani G, Potosky A, Lipscomb J. Analyzing health care costs: a comparison of statistical methods motivated by Medicare colorectal cancer charges. Biostatistics. 2004;1:1–23.
    1. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2014. Available at: . Accessed August 10, 2014.
    1. Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30:1374–1383. doi: 10.2337/dc07-0048.
    1. Wolf AM, Siadaty M, Yaeger B, et al. Effects of lifestyle intervention on health care costs: improving control with activity and nutrition (ICAN) J Am Diet Assoc. 2007;107:1365–1373. doi: 10.1016/j.jada.2007.05.015.
    1. Russell LB. Preventing chronic disease: an important investment, but don’t count on cost savings. Health Aff. 2009;28:42–45. doi: 10.1377/hlthaff.28.1.42.
    1. Krukowski RA, Tilford JM, Harvey-Berino J, West DS. Comparing behavioral weight loss modalities: incremental cost-effectiveness of an internet-based versus an in-person condition. Obesity. 2011;19:1629–1635. doi: 10.1038/oby.2010.341.
    1. Gustafson A, Khavjou O, Stearns SC, et al. Cost-effectiveness of a behavioral weight loss intervention for low-income women: the weight-wise program. Prev Med. 2009;49:390–395. doi: 10.1016/j.ypmed.2009.09.007.
    1. Roux L, Kuntz KM, Donaldson C, Goldie SJ. Economic evaluation of weight loss interventions in overweight and obese women. Obesity. 2006;14:1093–1106. doi: 10.1038/oby.2006.125.
    1. O’Grady MJ, Capretta JC. Assessing the economics of obesity and obesity interventions. Washington, D.C: Campaign to End Obesity; March; 2012.
    1. Olsen J, Willaing I, Ladelund S, Jorgensen T, Gundgaard J, Sorensen J. Cost-effectiveness of nutritional counseling for obese patients and patients at risk of ischemic heart disease. Int J Technol Assess Health Care. 2005;21:194–202.
    1. Galani C, Schneider H, Rutten FF. Modelling the lifetime costs and health effects of lifestyle intervention in the prevention and treatment of obesity in Switzerland. Int J Public Health. 2007;52:372–382. doi: 10.1007/s00038-007-7014-9.
    1. Diabetes Prevention Program Research G The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012;35:723–730. doi: 10.2337/dc11-1468.
    1. Diabetes Prevention Program Research Group Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518–2523. doi: 10.2337/diacare.26.9.2518.
    1. Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess. 2004;8:iii–iv. doi: 10.3310/hta8210.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere